MaxCyte, Inc. Director/PDMR Shareholding (6925A)
01 October 2020 - 4:00PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6925A
MaxCyte, Inc.
01 October 2020
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director Dealings
Maryland, USA - 1 October 2020 : MaxCyte (LSE: MXCT, MXCS ), the
global cell-based medicines and life sciences company, announces
that J. Stark Thompson, Non-Executive Chairman of the Company, has
exercised options over 25,000 shares of common stock of 0.1 pence
of the Company ("Common Stock") ("Exercise"). In order to fund a
near term personal tax liability, the 25,000 new shares of Common
Stock issued pursuant to the Exercise ("New Common Stock") have
today been sold by Dr Thompson at a price of GBP3.55 pence per
Common Stock ("Sale"). Dr Thompson has no current intention of
making further sales of MaxCyte shares.
Following the Exercise and Sale, Dr Thompson's holding of Common
Stock remains unchanged at a total of 110,918 Common Stock
representing a total of 0.14% of the issued share capital of the
Company. Dr Thompson holds a
further 241,333 options over Common Stock.
Total voting rights
The New Common Stock will be allocated out of the common stock
the subject of the block listing announced on 2 May 2017. The New
Common Stock will rank pari passu with the existing shares of
common stock of the Company. The total issued stock capital of the
Company following the above will be 77,305,169 shares of common
stock. Shareholders in the Company may use this figure as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the stock capital of the Company.
The number of unrestricted shares of Common Stock trading under
the symbol 'MXCT' is 67,405,080 and the number of restricted shares
of Common Stock trading under the symbol 'MXCS' is 9,900,089.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name J. Stark Thompson
========================================== ============================================
2 Reason for the notification
========================================================================================
a) Position/status Non-Executive Chairman and PDMR
========================================== ============================================
b) Initial notification/Amendment Initial notification
========================================== ============================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
========================================================================================
a) Name MaxCyte, Inc.
========================================== ============================================
b) LEI 54930053YHXULRFCU991
========================================== ============================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
========================================================================================
a) Description Ordinary shares of 0.1 pence each
of the financial
instrument,
type of instrument
========================================== ============================================
b) Identification US57777K1060
Code
========================================== ============================================
c) Nature of the Exercise of options and Sale of Common
transaction Stock by PDMR
========================================== ============================================
d) Price(s) and Price(s) Volume(s)
volume(s)
========================================== ========================== ================
GBP3.55 25,000
========================================================================== ================
e) Aggregated information N/A (Single Transaction)
- Aggregated
volume
- Price
========================================== ============================================
f) Date of the 1.10.20
transaction
========================================== ============================================
g) Place of the London Stock Exchange, AIM Market (XLON)
transaction
========================================== ============================================
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (AIM:MXCT, MXCL) and is
headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEAENEDEAEEAA
(END) Dow Jones Newswires
October 01, 2020 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024